澳洲 CSL 攜手亞馬遜雲端部門強化研究管線

9月29日（路透）— 澳洲生物科技公司 CSL 週二表示，正與亞馬遜（Amazon）的雲端事業合作，在其研究與臨床開發管線中運用人工智慧和雲端技術。Sept 29 (Reuters) - Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline.

以下是更多細節：Here are some more details:

• CSL 表示，與亞馬遜雲端服務（Amazon Web Services, AWS）的合作，將使 CSL 科學家能分析複雜的科學數據，並在藥物發現流程較早階段找出潛在藥物標的，有助於加速研究並縮短開發時程。• The partnership with Amazon Web Services (AWS) will enable CSL's scientists to analyse complex scientific data and identify potential drug targets earlier in the discovery process, helping to accelerate research and shorten development timelines, the company said.

• 在臨床方面，CSL 表示，也將使用 AWS 的雲端和 AI 工具，降低在試驗方案撰寫、資料管理和送件流程中的人工工作負荷。• On the clinical front, CSL said it will also use AWS's cloud and AI tools to reduce manual workloads in protocol drafting, data management, and submission processes.

• CSL 目標是讓實驗室工作與運算工作更緊密連結，使實驗發現能更快反映在研究模型和決策中。• The firm aims to link laboratory and computational work more closely, enabling experimental findings to inform research models and decisions faster.

• 這項與總部位於西雅圖的 AWS 展開的合作，是在美國總統川普於9月初宣布與多家國際製藥公司達成新一輪藥價協議之後；CSL 也在其中。• The partnership with Seattle-based AWS comes after US President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies, including CSL, in early September.

• 8月中旬，CSL 公布優於預期的全年基礎獲利，並預估在核心血漿事業帶動下，2027年將出現成長。• In mid-August, CSL posted better-than-expected annual underlying earnings and forecast growth in 2027 on the back of its core plasma division.

• 格林威治標準時間0023時，CSL 股價大致持平，報181.9澳元。• Shares of CSL were largely unchanged at A$181.9, as of 0023 GMT.

（班加羅爾 Aamir Shaik Khalid 報導；Subhranshu Sahu 編輯）(Reporting by Aamir Shaik Khalid in Bengaluru; Editing by Subhranshu Sahu)